Rhizome AI

Always know what the FDA thinks

Winter 2026ActiveB2BSaaSBiotechJersey City, NJ, USA; Remote

Company

$8 trillion dollars of market cap needs to know what the FDA thinks. Rhizome AI makes that happen. Users ask a question and get an answer backed by up to 1,000 documents, where each statement has a citation. The data is pulled from terabytes of authoritative regulatory & clinical databases. Chetan started his career as a research engineer, but quickly realized he enjoyed building more than research. He joined EvolutionaryScale as their sole founding product engineer, launching their developer-scientist platform and scaling to tens of thousands of users and billions of API calls. He was also #16 at Instabase helping banks with document & imaging processing, closing $7m as the technical lead. Being so plugged into the AI world, he saw lots of AI drug discovery companies, but very few AI companies focused on bringing those drugs to market. Talking to people, it quickly became clear that a big, expensive barrier was understanding FDA thinking.

Verdict

High Signal

Market Opportunity

Regulatory affairs for pharma/biotech/medtech is a massive B2B market — the description cites $8T market cap dependent on FDA decisions, and ICP is clearly defined (regulatory affairs managers, VPs, consultants at biotech, pharma, medtech). Pricing tiers from $400/mo to custom enterprise shows clear monetization. Every drug, device, and combination product company globally needs this, creating a large and recurring spend category.

High Signal

Founder Signal

Chetan Mishra has ~7 years of progressively senior engineering roles. At Instabase (employee #16, grew to 250), he was technical lead closing $7M in deals with banks/insurers over 3 years. At EvolutionaryScale (employee #15, first product engineer), he built and scaled forge.evolutionaryscale.ai to billions of API calls, hundreds of GPUs, managing a team of 5. Direct AI infrastructure and enterprise sales experience is highly relevant to Rhizome's product. University of Virginia background is irrelevant given the track record.

Medium Signal

Competition

No direct competitor data returned in research, but the space overlaps with general legal/regulatory AI tools (Harvey, Lexis+AI) and pharma-specific document tools. Rhizome's moat is the curated 2.5TB corpus of regulatory-specific data across 30 datasets and 6 markets, plus the hallucination-reduction fine-tuning. The niche focus on FDA/EMA regulatory intelligence rather than general legal AI is a meaningful differentiator, but well-funded players could expand into this vertical.

High Signal

Product

20+ paying customers, 2,800+ answers served, clear pricing page ($400/mo project, $3,500/yr professional, $20K/yr business, custom enterprise), and a live demo with source-cited answers. Multiple named testimonials from VP Regulatory Affairs, Directors at Top-5 Pharma, and Principal Consultants with emotionally strong quotes ('I would cry if I lost access'). 2.5TB corpus across 30 regulatory datasets in 6 markets is a concrete, verifiable product claim.

OverallA Tier

Rhizome is a focused, well-executed B2B SaaS product with real paying customers, clear pricing, and genuine testimonials from senior pharma/regulatory professionals. Chetan's background — enterprise AI at Instabase, scaled developer platform at EvolutionaryScale — is directly applicable and unusually strong for an early-stage solo founder. The product has a defensible corpus moat (2.5TB regulatory data across 30 datasets) and the ICP is crystal clear. Main risk is that it's a solo founder and the competition ceiling from large legal/regulatory AI players (Harvey, etc.) could compress the market if they move into pharma regulatory specifically. At 20+ customers and this early, the growth trajectory and ability to land enterprise contracts will determine whether this is an A or S.

Active Founders

Chetan Mishra

Founder

I help life sci companies know what the FDA thinks. In the past I've: - closed 7m as the technical lead to banks/insurance companies for Instabase (>200m raised) - built and launched a scientist developer platform for drug discovery for EvolutionaryScale (140m raised) - grown a gigwork app's usage from 3.5k to 35k DAU in 9 months for Para (>20m raised) Software engineer by background. Started of training deep learning models in a research group in the image-text domain.

Rhizome AI

TierA Tier

BatchWinter 2026

Team Size1

StatusActive

LocationJersey City, NJ, USA; Remote